Arteriovenous fistula thrombosis in patients on regular hemodialysis: A report of 171 patients

Archives of Iranian Medicine

Volumn 9, Issue 1, 2006, Pages 26-32

  Roozbeh, Jamshid ^a   Serati, Ali Reza ^b   Malekhoseini, Seyed Ali ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anticardiolipin antibody (ACLA); Eprex; Fistula; Fistula thrombosis

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTERIOVENOUS FISTULA; ARTERIOVENOUS FISTULA THROMBOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOASSAY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS; ULTRAFILTRATION;

ANTIBODIES, ANTICARDIOLIPIN; ARTERIOVENOUS SHUNT, SURGICAL; CATHETERS, INDWELLING; EPOETIN ALFA; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOSIS;

EID: 31144473509     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. US renal data system (USRDS) 1997 annual data report. The National Institute of Health, National Institute of Diabetes, Digestive, and Kidney Disease, Bethesda. MD1997.
2. Woods JD, Turenne MN, Strawderman RL, et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis. 1997; 30: 50-57.
3. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Circulation. 1989; 80: 1726-1736.
4. Windus DW, Jendrisak M, Delmez JA. Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age. Am J Kidney Dis. 1992; 19: 448-452.
5. Culp K, Flanigan M, Taylor L, Rothstein M. Vascular access thrombosis in new hemodialysis patients. Am J Kidney Dis. 1995; 26: 341-346.
6. Churchill DN, Taylor DW, Cook RJ, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992: 19: 214-234.
7. Goldwasser P, Michel MA, Collier J, et al. Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis. 1993; 22: 215-225.
8. Fermo I, Vigano D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early onset of venous and arterial occlusive disease. Ann Inter Med. 1995; 23: 747-753.
9. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986; 146: 2153-2156.
10. Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation. 1999; 67: 90-93.
11. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anticardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol. 1999; 51: 116-121.
12. Laurell AB, Nilsson IM. Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction, a study in two cases. J Lab Clin Med. 1957; 49: 694-707.
13. Harris EN, Gharavi AE, Loizou S, et al. Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol. 1985; 16: 1-6.
14. Sitter T, Schiffl H. Anticardiolipin antibodies in patients on regular hemodialysis: an epiphenomenon? Nephron. 1993; 64: 655-656.
15. Garcia-Martin F, De Arriba G, Carrascosa T, et al. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant. 1991; 6: 543-547.
16. Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995; 26: 347-352.
17. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol. 1985; 62: 738-745.
18. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986; 41: 8-15.
19. Sitter T, Spannagl M, Schiffl H. Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of replacement therapy in comparison to patients with systemic lupus erythematosus. Ann Hematol. 1992; 65: 79-82.
20. Gronhagen-Riska C, Teppo AM, Helantera A, Honkanen E, Julkunen H. Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. BMJ. 1990; 300: 1696-1697.
21. Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol. 1982; 13: 121-129.
22. Chew SL, Lins RL, Daelemans R, Zachee P, De Cleck LS, Vermylen J. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant. 1992; 14: 1194-1198.
23. Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995; 26: 347-352.
24. Carroll P, Stafford D, Schwartz RS, Stollar BD. Murine monoclonal anti-DNA autoantibodies bind to endogenous bacteria. J Immunol. 1985; 135: 1086-1090.
25. Quereda C, Pardo A, Lamas S, et al. Lupus-like in vitro anticoagulant activity in end-stage renal disease. Nephron. 1998; 49: 39-44.
26. Fabrizi F, Sangiorgio R, Pontoriero G, et al. Antiphospholipid (aPL) antibodies in end-stage renal disease. J Nephrol. 1999; 12: 89-94.
27. Page B, Yazbeck F, Zingraff J, et al. Clotting of vascular access in dialysis patients associated ACLA. Nephrol Dial Transplant. 1992; 7: 733.
28. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis. 2002; 39: 92-101.
29. Livingston CK, Potts JR 3rd. Upper arm arteriovenous fistulas as a reliable access alternative for patients requiring chronic hemodialysis. Am Surg. 1999; 65: 1038-1042.
30. Cantelmo NL, LoGerfo FW, Menzoian JO. Brachiobasilic and brachiocephalic fistulas as secondary angioaccess routes. Surg Gynecol Obstet. 1982; 155: 545-548.
31. Dunlop MG, Mackinlay JY, Jenkins AM. Vascular access: experience with the brachiocephalic fistula. Ann R Coll Surg Engl. 1986; 68: 203-206.
32. Bender MH, Bruyninckx CM, Gerlag PG. The Gracz arteriovenous fistula evaluated. Results of the brachiocephalic elbow fistula in hemodialysis angioaccess. Eur J Vasc Endovasc Surg. 1995; 10: 294-297.
33. Kalman PG, Pope M, Bhola C, Richardson R, Sniderman KW. A practical approach to vascular access for hemodialysis and predictors of success. J Vasc Surg. 1999; 30: 727-733.
34. Golledge J, Smith CJ, Emery J, Farrington K, Thompson HH. Outcome of primary radiocephalic fistula for haemodialysis. Br J Surg. 1999; 86: 211-216.
35. Miller PE, Tolwani A, Luscy CP, et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int. 1999; 56: 275-280.
36. Ascher E, Gade P, Hingorani A, et al. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg. 2000; 31: 84-92.
37. Leapman SB, Boyle M, Pescovitz MD, et al. The arteriovenous fistula for hemodialysis access: gold standard or archaic relic? Am Surg. 1996; 62: 652-656.
38. Prischl FC, Kirchgatterer A, Brandstatter E, et al. Parameters of prognostic relevance to the patency of vascular access in hemodialysis patients. J Am Soc Nephrol. 1995; 6: 1613-1618.
39. Bern MM, Klumpar DI, Wheeler WE, Davis GL. Factor VIII complex in chronic renal failure: influence of protein C, fibrinolysis, and diabetes mellitus. Thromb Res. 1983; 31: 177-186.
40. Winter M, Needham J, Mackie I, Cameron JS. Impaired vessel wall response to venous occlusion in patients with CRF on maintenance hemodialysis. Clin Nephrol. 1984; 22: 307-313.
41. Kristensen SD, Knudsen F, Nielsen AH, Ring T. Decreased platelet sensitivity to prostacyclin (epoprosteinol) during hemodialysis. Clin Nephrol. 1984; 21: 230-234.
42. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis. 1994; 23: 828-835.
43. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992; 7: 235-239.
44. Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kid Int. 1993; 44: 182-190.
45. Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol. 1994; 4: 1809-1813.
46. Ikegaya N, Yamamoto T, Takeshita A, et al. Elevated erythropoietin receptor and transforming growth factor-beta1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000; 11: 928-935.